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Introduction
Rapid diagnostic technologies are revolutionizing the
clinical microbiology laboratory. Next generation
sequencing (NGS) is poised to be the next pow-
erful tool in standard clinical laboratories build-
ing on the widespread adoption of multiplex poly-
merase chain reaction (PCR) panels and matrix-assisted
laser desorption/ionization-time of flight (MALDI-
TOF) technology.[1] NGS can provide a quantitative
analysis of all non-human DNA or RNA in a sam-
ple without requiring growth on a traditional medium.
This improves the diagnostic yield of infections that are
difficult to culture due to biofilm production, such as
prosthetic joint infections.[2] As these technologies be-
come faster and cheaper, research efforts are urgently
needed to guide clinicians to wider applications of
NGS, including use in non-sterile sites, such as lower
and upper respiratory tract samples. The diagnostic
utility of NGS of respiratory samples has already been
noted in cases of pneumonia caused by pathogens that
are difficult to identify through conventional testing.[3,
4] However, the use of NGS as a diagnostic tool in
community-acquired pneumonia (CAP) remains to be
elucidated. The characterization of the respiratory mi-
crobiome in clinical practice may improve the diagno-
sis and therefore the treatment of CAP. However, with-
out adequate research, using NGS in patients with sus-
pected CAP may unnecessarily accelerate antimicrobial
prescribing simply by providing the names of all com-
mensal organisms present in a respiratory sample.
A clinical diagnosis of CAP has limited utility in differ-
entiating bacterial versus non-bacterial causes of infec-
tions. Clinical respiratory cultures more often than not
fail to yield a definitive causative pathogen. Biomark-
ers, such as procalcitonin, have been studied heavily in
the management of CAP but have limitations, such as
low levels during early course of infections and false
negative results.[5] The need for additional objective
criteria to assist in the diagnosis of CAP is therefore
needed. In this opinion piece, we present a research
framework that can be used to evaluate the role of
NGS in hospitalized patients with a clinical diagnosis
of CAP.
Research framework to study NGS in CAP
In our opinion, prospective clinical trials can be per-
formed by randomizing patients with a clinical sus-
picion of CAP into two groups (Figure 1). The NGS
group would have their NGS results shared and dis-
cussed with the treatment team to guide anti-infective
therapy. The standard of care (SOC) group would have
their NGS results blinded to the treatment team, and
therefore, treatment would be based on standard of
care.
In patients with a working diagnosis of CAP, biomark-
ers indicative of bacterial infection (e.g., procalcitonin)
can be evaluated together with NGS. A proposed re-
search framework for exploring NGS and biomarkers
in hospitalized patients with a working diagnosis of
CAP is outlined in Figure 2.
This proposed research framework will facilitate four
possible clinical scenarios. Several questions are pro-
posed below to guide clinical research based on the
four clinical settings.
Scenario #1
In Scenario #1, a patient would have a working diag-
nosis of CAP, with biomarkers and NGS results sug-
gestive of bacterial pneumonia. In these patients, NGS
may demonstrate a clinical benefit by identifying an or-
ganism that is not adequately treated by the empiric
regimen and not isolated from standard clinical cul-
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Figure 1. Study design for the evaluation of NGS in patients with CAP.























NGS result suggestive of CAP etiology
Figure 2. Proposed framework for research using next generation sequencing in patients with suspected community-acquired bacterial pneu-
monia (CABP).
Abbreviations: CABP, community-acquired bacterial pneumonia; CAP, community-acquired pneumonia; PCT, procalcitonin.
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tures. However, antimicrobials may be unnecessarily
escalated without a clinical benefit, leading to increased
risk of antimicrobial adverse events, selection for multi-
drug resistant organisms, or risk of Clostridioides difficile
infection. Additionally, NGS provides little informa-
tion on antimicrobial susceptibility, thereby increasing
the likelihood of antimicrobial escalation in the NGS
group. Selection of definitive antimicrobial would be
challenging if the predominant organism identified is
not traditionally associated with CAP.
Other studies in Scenario #1 include describing the
yield of concordant NGS results from different anatom-
ical samples. For example, does NGS of oropharyngeal
swabs match NGS results from lower respiratory sam-
ples (i.e., sputum or bronchoalveolar lavage [BAL])?
Does NGS of a patient’s blood or urine identify the
causative pathogen?
Scenario #2
In Scenario #2, a patient will have biomarkers sugges-
tive of a bacterial infection, but the NGS result does not
identify a bacterial pathogen. Research studies in Sce-
nario #2 could focus on the ability of NGS to guide clin-
icians towards an alternative diagnosis. In comparing
the NGS group to the SOC group, an outcome of inter-
est may be time to alternative diagnosis or rate of al-
ternative diagnosis at the point of discharge. However,
the threshold for designating an NGS of a respiratory
sample as “positive” for bacterial organisms remains to
be defined. Should a different threshold for positivity
of NGS be used for immunocompromised patients if
CABP is still the most likely etiology?
Because Scenario #2 describes discordant procalcitonin
and NGS results, researchers need to be cautious in sit-
uations with potentially falsely elevated procalcitonin
concentrations or false negative NGS results. A possi-
ble research study could examine the influence of an-
timicrobials prior to collection of samples for NGS. Ad-
ditionally, a study could be done to examine the influ-
ence of viral respiratory infections leading to false neg-
ative NGS results.
Scenario #3
In Scenario #3, a patient will have an NGS result of a
respiratory specimen that is suggestive of CABP but
will not have significantly elevated biomarkers. As
in Scenario #2, the procalcitonin and NGS results are
discordant and therefore would need to be explained.
Atypical organisms (Mycoplasma pneumoniae, Chlamy-
dophila pneumoniae, and Legionella pneumoniae) in CABP
may not cause a significant elevation in procalcitonin.
Additionally, fungal pathogens may cause respiratory
infections in immunocompromised patients. However,
the predominance of a low-virulence bacteria may sim-
ply be a sign of bacterial dysbiosis and may not require
antimicrobial therapy for CABP.
Scenario #4
In Scenario #4, a patient will demonstrate concordant
procalcitonin and NGS results suggesting an unlikely
diagnosis of CABP. This should result in prompt dis-
continuation of antimicrobials for CABP in the NGS
group. Not only should patients benefit from decreased
risk of unnecessary antimicrobials, but they may also
benefit from additional diagnoses or treatments once
CABP has been removed from the differential. Such
benefits have been demonstrated by de Jong et al.,
where procalcitonin-guided discontinuation of antimi-
crobials resulted in improved 28-day mortality in crit-
ically ill patients.[6] However, patients in Scenario #4
may still have diagnostic uncertainties as some organ-
isms, such as Mycobacterium tuberculosis or Bacillus an-
thracis, may prompt treatment regardless of NGS pre-
dominance.
Conclusion
Significant research questions remain regarding the
clinical use of NGS in CAP. NGS in CAP may result
in a diagnostic pathway that can quickly and reliably
differentiate between bacterial respiratory tract infec-
tions versus other causes. However, the clinical util-
ity of widespread or routine NGS remains largely un-
known. Prospective randomized controlled trials are
urgently needed to define the role of NGS in patients
with CAP. Our proposed research framework outlines
a programmatic approach to designing research of NGS
in CAP.
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